Orphan designation: 2-(3-(3,5-Dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol Treatment of myelofibrosis, 13/10/2023 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 1 February 2024 - 10:58

Orphan designation: 2-(3-(3,5-Dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol Treatment of myelofibrosis, 13/10/2023 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2844

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters